Skip to main content

Advertisement

SpringerLink
Log in

Occult Primary Medullary Thyroid Carcinoma Presenting with Pituitary and Parotid Metastases: Case Report and Review of the Literature

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Wells SA, Franz C. Medullary carcinoma of the thyroid gland. World J Surg 24:952-956, 2000.

    Article  PubMed  Google Scholar 

  2. Mills, Stacy E. Pathology of the thyroid and parathyroid disease. In: Sternberg’s Diagnostic Surgical Pathology. 6th ed.

  3. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 276(19):1575-1579, 1996.

    Article  PubMed  CAS  Google Scholar 

  4. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol 61:299–310, 2004.

    Article  Google Scholar 

  5. DeLellis R.A., Lloyd R.V., Heitz, P.U., Eng C. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyon 2004; 86–91.

  6. Grozinsky-Glasberg S, Benbassat CA, Tsvetov G, Feinmesser R, Peretz H, Shimon I, Lapidot M. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid 17(6):549–556, 2007.

    Article  PubMed  Google Scholar 

  7. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, Schlumberger M. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88(5):2070–2075, 2003.

    Article  PubMed  CAS  Google Scholar 

  8. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229(6):880–888, 1999.

    Article  PubMed  CAS  Google Scholar 

  9. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63(6):319–42, 1984.

    CAS  Google Scholar 

  10. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 31(10):1960–1965, 2007.

    Article  PubMed  Google Scholar 

  11. Quayle FJ, Moley JF. Medullary thyroid carcinoma: including MEN2A and 2B syndromes. J Surg Oncol 89:122–129, 2005.

    Article  PubMed  Google Scholar 

  12. Chen H, Sipper RS, O’Dorisio MS, Vinik Al, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39(6):775–783, 2010.

    Article  PubMed  Google Scholar 

  13. Albores-Saavedra J, LiVolsi VA, Williams ED. Medullary carcinoma. Semin Diagn Pathol 2:137–146, 1985.

    PubMed  CAS  Google Scholar 

  14. Sironi M, Cozzi L, Pareschi R, Spreafic GL, Assi A. Occult sporadic medullary microcarcinoma with lymph node metastases. Diagn Cytopathol 21(3):203–206, 1999.

    Article  PubMed  CAS  Google Scholar 

  15. Beressi N, Campos JM, Beressi JP, Franc B, Niccoli-Sire P, Conte-Devolx B, Murat A, Caron P, Baldet L, Kraimps JL, Cohen R, Bigorgne JC, Chabre O, Lecomte P, Modigliani E. Thyroid. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid 8(11):1039–1044, 1998.

    Article  PubMed  CAS  Google Scholar 

  16. Fassett DR, Couldwell WT. Metastasis to the pituitary gland. Neurosurg Focus 16(4):E8, 2004.

    PubMed  Google Scholar 

  17. Teears RJ, Silverman EM. Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland. Cancer 36:216–220, 1975.

    Article  PubMed  CAS  Google Scholar 

  18. Asa SL. Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med 132:1231–1240, 2008.

    PubMed  Google Scholar 

  19. Morita A, Meyer FB, Laws ER Jr. Symptomatic pituitary metastases. J Neurosurg 89: 69–73, 1998.

    Article  PubMed  CAS  Google Scholar 

  20. Roessmann U, Kaufman B, and Friede RL. Metastatic lesions in the sella turcica and pituitary gland. Cancer 25:478–480, 1970.

    Article  PubMed  CAS  Google Scholar 

  21. Bhatoe HS, Badwal S, Dutta V, Kannan N. Pituitary metastasis from medullary carcinoma of thyroid: case report and review of literature. J Neurooncol 89:63–67, 2008.

    Article  PubMed  Google Scholar 

  22. Santarpia L, Gagel RF, Sherman SI, Sarlis NJ, Evans DB, Hoff AO. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck 31(3): 419–423, 2009.

    Article  PubMed  Google Scholar 

  23. Batsakis JG. Pathology consultation. Parotid gland and its lymph nodes as metastatic sites. Ann Otol Rhinol Laryngol 92:209–210, 1983.

    PubMed  CAS  Google Scholar 

  24. Nuyens M, Schüpbach J, Stauffer E, Zbären P. Metastatic disease to the parotid gland. Otolaryngol Head Neck Surg 135:844–848, 2006.

    Article  PubMed  Google Scholar 

  25. Mohyuddin H, Mahrous A, Sharma V, Gluckman P. Parotid mass: an unusual presentation of gastroesophageal malignancy. J Laryngol Otol 125(5):546–548, 2011.

    Article  PubMed  CAS  Google Scholar 

  26. Ulubas B, Ozcan C, Polat A. Small cell lung cancer diagnosed with metastasis in parotid gland. J Craniofac Surg 21(3):781–783, 2010.

    Article  PubMed  Google Scholar 

  27. Moutaouakil A, Baha AT, and Amraoui A. Metastase choroidienne d’un carcinome de la thyroide (a propos d’un cas). Bull Soc Belge Ophtalmol 288:19–22, 2003.

    PubMed  Google Scholar 

  28. Pelosi S, Genden EM. Medullary thyroid carcinoma metastatic to the parotid gland. The Laryngoscope (Meeting Abstracts) 119(Supplement S3):S253, 2009.

  29. Ebert EC. The thyroid and the gut. J Clin Gastroenterol 44:402–406, 2010.

    PubMed  CAS  Google Scholar 

  30. Krafts KP, Pambuccian SE. Romanowsky staining in cytopathology: history, advantages and limitations. Biotech Histochem 86(2):82–93, 2011.

    Article  PubMed  CAS  Google Scholar 

  31. Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, Folpe AL. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 13(3):238–242, 2000.

    Article  PubMed  CAS  Google Scholar 

  32. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol 21:192–200, 2008.

    PubMed  CAS  Google Scholar 

  33. Mills SE. Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas. Mod Pathol 15(3):264–278, 2002.

    Article  PubMed  Google Scholar 

  34. Wenig BM, Hyams VJ, Heffner DK. Moderately differentiated neuroendocrine carcinoma of the larynx. A clinicopathologic study of 54 cases. Cancer 62:2658–2676, 1988.

    Article  PubMed  CAS  Google Scholar 

  35. Machens A, Haedecke J, Hinze R, Thomusch O, Schneyer U, Dralle H. Hypercalcitoninemia in a sporadic asymptomatic neuroendocrine tumor of the pancreatic tail. Dig Surg 17(5):522–4, 2000.

    Article  PubMed  CAS  Google Scholar 

  36. Alapat DV, Ain KB, Sloan DA, Monaghan KG, Karabakhtsian RG. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocrine 39(2):148-52, 2011.

    Article  PubMed  CAS  Google Scholar 

  37. Leboulleux S, Baudin E, Young J, Caillou B, Lazar V, Pellegriti G, Ducreux M, Schaison G, Schlumberger M. Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. Eur J Endocrinol 140:187–191, 1999.

    Article  PubMed  CAS  Google Scholar 

  38. Milione M, Seregni E. Pathological diagnosis and tumor markers. Tumori 96: 810–816, 2010.

    PubMed  Google Scholar 

  39. Bajetta E, Ferrari L,Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86: 858–865, 1999.

    Article  PubMed  CAS  Google Scholar 

  40. Rosai and Ackerman’s Surgical Pathology, 10th edn; 48, 329–330, 526–531, 822–840.

  41. Su CH, Chang H, Chen CJ, Liu LC, Wang HC, Lane HY, Bau DT. The carcinoembryonic antigen as a potential prognostic marker for neuroendocrine carcinoma of the breast. Anticancer Res 32(1):183–188, 2012.

    PubMed  Google Scholar 

  42. Kleinschmidt–DeMasters. Pituitary Gland. In: Rosai and Ackerman’s Surgical Pathology, 10th edn.

  43. Coons SW, Etrada SI, Gamez R, White WL. Cytokeratin CK7 and CK 20 expression in pituitary adenomas. Endocr Pathol 16: 201–210, 2005.

    Article  PubMed  CAS  Google Scholar 

  44. Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas NK. Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker?. JNEN 68(5):482–8, 2009.

    CAS  Google Scholar 

  45. Takei H, Goodman JC, Tanaka S, Bhattacharjee MB, Bahrami A Powell, SZ. Pituicytoma incidentally found at autopsy. Pathol Int 55:745–749, 2005.

    Article  PubMed  Google Scholar 

  46. Salame K, Ouaknine GE, Yossipov J, Rochkind S. Paraganglioma of the pituitary fossa: diagnosis and management. J Neurooncol 54(1):49–52, 2001.

    Article  PubMed  CAS  Google Scholar 

  47. McLaughlin DM, Gray WJ, Jones FG, Mirakhur M, McCance DR, Sheridan B, Atkinson AB. Plasmacytoma: an unusual cause of a pituitary mass lesion. A case report and a review of the literature. Pituitary 7(3):179–81, 2004.

    Article  PubMed  CAS  Google Scholar 

  48. Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E and Schlumberger M. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92(11):4185–4190, 2007.

    Article  PubMed  CAS  Google Scholar 

  49. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63(6):319–342, 1984.

    CAS  Google Scholar 

  50. O’Riordain DS, O’Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, van Heerden JA. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116(6):1017–1023, 1994.

    PubMed  Google Scholar 

  51. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88(5):1139–1148, 2000.

    Article  PubMed  CAS  Google Scholar 

  52. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67(4):801–805, 1988.

    Article  PubMed  CAS  Google Scholar 

  53. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6(4):305–310, 1996.

    Article  PubMed  CAS  Google Scholar 

  54. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC). Br J Cancer 83(6):715–718, 2000.

    Article  PubMed  CAS  Google Scholar 

  55. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73(2):432–436, 1994.

    Article  PubMed  CAS  Google Scholar 

  56. Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, Kirichek O, Thakker RV, Talbot DC. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 104(7):1067–1070, 2011.

    Article  PubMed  CAS  Google Scholar 

  57. Fürstenberger G, Schmid P, Duquesne A, Ammann M, Senn HJ. Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy. Cancer Chemother Pharmacol 61(2):347–348, 2008.

    Article  PubMed  Google Scholar 

  58. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406, 2006.

    Article  PubMed  CAS  Google Scholar 

  59. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B.Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13(10):2986–2991, 2007.

    Article  PubMed  CAS  Google Scholar 

  60. R. L. Fine, D. R. Fogelman, S. M. Schreibman. Effective Treatment of Neuroendocrine Tumors With Temozolomide and Capecitabine. Journal of Clinical Oncology (Meeting Abstracts) 23(Suppl 16S):4216, 2005.

    Google Scholar 

  61. Paiva CE, Michelin OC. Use of capecitabine in refractory metastatic medullary thyroid carcinoma. Thyroid 18(5):587, 2008.

    Article  PubMed  Google Scholar 

  62. Gilliam LK, Kohn AD, Lalani T, Swanson PE, Vasko V, Patel A, Livingston RB, Pickett CA.Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid 16(8):801–810, 2006.

    Article  PubMed  CAS  Google Scholar 

  63. Labidi SI, Gravis G, Tarpin C, Brun V, Viens P. Medullary thyroid cancer treated by capecitabine. Anticancer Drugs 18(7):831–834, 2007.

    Article  PubMed  CAS  Google Scholar 

  64. Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Curr Opin Oncol 22(4):381–386, 2010.

    Article  PubMed  CAS  Google Scholar 

  65. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5):646–74, 2011.

    Article  PubMed  CAS  Google Scholar 

  66. Zhang J, Yang PL, Gray NS.Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9(1):28–39, 2009.

    Article  PubMed  Google Scholar 

  67. Spector E, Franklin MJ, Truskinovsky AM, Dudek AZ. Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta Oncol 49(1):104–106, 2010.

    Article  PubMed  CAS  Google Scholar 

  68. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28(14):2323–2330, 2010.

    Article  PubMed  CAS  Google Scholar 

  69. Cohen, EEW, Needles, BM, Cullen, KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol (Meeting Abstracts) 26:6025, 2008.

    Google Scholar 

  70. Ravaud, A, de la Fouchardière, C, Courbon, F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol (Meeting Abstracts) 26:6058, 2008.

    Article  Google Scholar 

  71. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794–801, 2009.

    Article  PubMed  CAS  Google Scholar 

  72. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28(5):767–72, 2010.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Minnesota, 420 Delaware St SE, Minneapolis, MN, 55455, USA

    Andrea Conway

  2. Hematology-Oncology Section, University of Minnesota, 420 Delaware St SE, Minneapolis, MN, 55455, USA

    Andres Wiernik

  3. Department of Pathology, Veterans Administration Health Care System, One Veterans Drive, Minneapolis, MN, 55417, USA

    Ajay Rawal & Hector Mesa

  4. Department of Neurosurgery, University of Minnesota, 420 Delaware St SE, Minneapolis, MN, 55455, USA

    Cornelius Lam

Authors
  1. Andrea Conway
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andres Wiernik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ajay Rawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cornelius Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hector Mesa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hector Mesa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Conway, A., Wiernik, A., Rawal, A. et al. Occult Primary Medullary Thyroid Carcinoma Presenting with Pituitary and Parotid Metastases: Case Report and Review of the Literature. Endocr Pathol 23, 115–122 (2012). https://doi.org/10.1007/s12022-012-9200-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-012-9200-4

Keywords

Search

Navigation